Heart failure with normal ejection fraction is often under diagnosed and certainly under treated in hemodialyzed patients. Because of the benefit of reducing heart rate, ivabradine, a pure heart-rate lowering agent without effects on blood pressure, is of potential therapeutic utility.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
ivabradine titrated to 7.5 mg BID
Chair of Cardiology Second Univesity of Naples
Naples, Italy
Echocardiofic changes of diastolic left ventricular function
Measures of diastolic left ventricular function (E and A velocity and deceleration time of mitral inflow and Doppler-Tissue-Imaging E velocity and their ratio) were assessed at baseline and at each scheduled time.
Time frame: baseline, 1, 3, 6, 9, 12 months
changes in NYHA class
Measures of New York Heart Association functional class stratified I to IV at baseline and at each scheduled time.
Time frame: baseline, 1,3,6,9,12 months
changes in 6-minutes walking test
American Thoracic Society At baseline and at each scheduled time a 6-minutes walking test were performed according ATS Statement. The following measures were analysed at starting and ending test: heart rate; blood pressure, dyspnea according the Borg scale, fatigue according the Borg scale, Spo2%;distance walked, symptoms.
Time frame: baseline, 1,3,6,9,12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.